Scarica l'app Stockscreener
167.95
2.81%
4.59
Pre-mercato:
170.33
2.38
+1.42%
Precedente Chiudi:
$163.36
Aprire:
$167.965
Volume 24 ore:
387.58K
Relative Volume:
0.35
Capitalizzazione di mercato:
$8.25B
Reddito:
$4.06B
Utile/perdita netta:
$413.08M
Rapporto P/E:
20.97
EPS:
8.01
Flusso di cassa netto:
$560.48M
1 W Prestazione:
+8.40%
1M Prestazione:
+13.96%
6M Prestazione:
+0.65%
1 anno Prestazione:
-23.76%
Intervallo 1D:
$166.99
$168.03
Intervallo di 1 settimana:
$146.26
$168.03
Portata 52W:
$91.86
$254.15
Charles River Laboratories International Inc Stock (CRL) Company Profile
Nome
Charles River Laboratories International Inc
Settore
Industria
Telefono
781-222-6000
Indirizzo
251 BALLARDVALE ST, WILMINGTON, MA
Confronta CRL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
167.95 | 8.02B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
466.71 | 161.42B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.89 | 135.99B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
540.68 | 42.78B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
119.47 | 33.01B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
194.24 | 31.85B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-05-08 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-03 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Downgrade | UBS | Buy → Neutral |
| 2024-11-18 | Downgrade | CLSA | Hold → Underperform |
| 2024-11-07 | Aggiornamento | CLSA | Underperform → Hold |
| 2024-10-23 | Iniziato | CLSA | Underperform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Sell |
| 2024-10-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-01 | Downgrade | Citigroup | Neutral → Sell |
| 2024-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Downgrade | Argus | Buy → Hold |
| 2024-06-07 | Iniziato | Mizuho | Neutral |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-09-13 | Iniziato | TD Cowen | Market Perform |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-02-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-12 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Iniziato | Guggenheim | Neutral |
| 2022-04-25 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-07 | Iniziato | Stephens | Overweight |
| 2022-02-17 | Reiterato | BofA Securities | Buy |
| 2022-02-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-17 | Reiterato | Deutsche Bank | Buy |
| 2022-02-17 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-17 | Reiterato | UBS | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-07-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-04-21 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-02-18 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Iniziato | SVB Leerink | Outperform |
| 2019-04-30 | Ripresa | Evercore ISI | Outperform |
| 2018-12-14 | Iniziato | Deutsche Bank | Buy |
| 2018-10-09 | Iniziato | UBS | Neutral |
| 2018-08-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
Charles River Laboratories International Inc. Stock Analysis and ForecastConsistent wealth multiplication - Autocar Professional
Is Charles River Laboratories International Inc. a good long term investmentOver 200% growth - Autocar Professional
What analysts say about Charles River Laboratories International Inc. stockOutstanding capital returns - jammulinksnews.com
What drives Charles River Laboratories International Inc. stock priceDynamic investment opportunities - jammulinksnews.com
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Labs Stock Rises on Plasmid DNA Deal with Ellys TeamNews and Statistics - IndexBox
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why Are Charles River Laboratories (CRL) Shares Soaring Today - Yahoo Finance
Charles River Joins Elly’s Team to Drive Rare Disease Gene Therapy Development - Business Wire
Here's What to Expect From Charles River Laboratories' Next Earnings Report - MSN
How Charles River Laboratories International Inc. stock reacts to Fed policy changesReal Chart Play - beatles.ru
Is it Prudent to Retain Charles River Stock in Your Portfolio Now? - MSN
Agree To Purchase Charles River Laboratories International At $150, Earn 21.4% Annualized Using Options - Nasdaq
Pharma Contract Research Organization (CRO) Services Market to Cross USD 36.66 Billion in 2025, Expanding at a CAGR of 10.04% - GlobeNewswire Inc.
Here's What To Expect From Charles River Laboratories' Next Earnings Report - Barchart.com
Is Charles River Laboratories International (NYSE:CRL) Using Too Much Debt? - simplywall.st
Why Charles River Laboratories International Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - beatles.ru
CFRA downgrades Charles River Labs (CRL) to a Hold - The Globe and Mail
Gordon Reid discusses Charles River Laboratories Intl. Inc - BNN Bloomberg
Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call - BioSpace
Charles River Laboratories International (CRL) is Expected to Gain as Industry Growth Resumes - Insider Monkey
U.S. Physical Therapy, Evolent Health, Charles River Laboratories, Moderna, and Intuitive Surgical Shares Are Falling, What You Need To Know - FinancialContent
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail
Evercore ISI Adjusts PT on Charles River Laboratories International to $180 From $170 - MarketScreener
This Microsoft Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Charles River Labs stock rating upgraded by Citi on DSA growth prospects - Investing.com Canada
Cathie Wood Agrees Circle IPO Is 'Crypto's ChatGPT Moment' — Warns Institutions That Ignoring The AI-Crypto Combo 'Just Isn't An Option'Charles River (NYSE:CRL) - Benzinga
Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
5 Revealing Analyst Questions From Charles River Laboratories’s Q1 Earnings Call - Yahoo Finance
Is Charles River Laboratories Stock Underperforming the S&P 500? - MSN
Charles River Laboratories: FDA Regulation And High Debt Are Signs Of Headwinds - Seeking Alpha
Charles River Laboratories: Riding the AI Drug Discovery Wave Amid Regulatory Crosscurrents - AInvest
Shareholders in Charles River Laboratories International (NYSE:CRL) are in the red if they invested three years ago - simplywall.st
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment | CRL Stock News - GuruFocus
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment - Business Wire
Charles River Laboratories International Inc Azioni (CRL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.84%
1.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):